| abstract |
Disclosed herein is a method of determining subject sensitivity to a WEE1 inhibitor, comprising obtaining or having obtained a biological sample from the subject, and performing or having performed at least one assay on the biological sample to determine if the subject has an altered DNA repair function of NBN, MRE11, RAD50 or MRE11-RAD50-NBN (MRN) protein complex. Also disclosed are methods of treating cancer with WEE1 inhibitors, and modifying the effective concentration based upon the sequence variation and function of NBN, MRE11, RAD50 or MRE11-RAD50-NBN (MRN) protein complex. |